secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeneDx Holdings Corp. (WGS)
CIK:        0001818331
Form:       8-K
Filed at:   2025-10-28T23:59:59+00:00
Accession:  0001818331-25-000128
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeneDx Q3 2025 revenue $116.7M (+52% YoY), adjusted net income $14.7M; raises full-year guidance
--------------------------------------------------------------------------------

- Q3 revenue $116.7M (+52% YoY); exome/genome revenue $98.9M (+65% YoY).
- Adjusted gross margin expanded to 74% from 64%; adjusted net income $14.7M vs $2.0M.
- Raised FY2025 revenue guidance to $425-428M; exome/genome growth 53-55% YoY.
- Granted FDA Breakthrough Device Designation for ExomeDx and GenomeDx tests.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818331/000181833125000128/0001818331-25-000128-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818331/000181833125000128/wgs-20251028.htm
  HTML page:      https://secwatch.observer/filing/0001818331-25-000128

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer